In its statement, DCGI said that they are working on a booster dose that would be effective against the Omicron variant. On Tuesday the drug got Emergency Use Authorization (EUA).
Gennova Chief Operating Officer Samit Mehta stated that “We injected our product in at least 4,000 healthy volunteers, and we haven’t noticed events like myocarditis or any other cardiac issues among the trial volunteers. Though adverse events have been reported in other mRNA vaccines, we didn’t witness anything like that in our trials.”
The company is planning to produce around four to five million dosages per month and the quantity can be quickly doubled if needed.